Effect of pegylated interferon-alpha-2a treatment on mental health during recent hepatitis C virus infection
Maryam Alavi, Jason Grebely, Gail V Matthews, Kathy Petoumenos, Barbara Yeung, Carolyn Day, Andrew R Lloyd, Ingrid Van Beek, John M Kaldor, Margaret Hellard, Gregory J Dore, Paul S Haber
Hepatology | WILEY | Published : 2012
Awarded by National Institutes of Health/National Institute of Drug Abuse
This work was supported by the National Institutes of Health/National Institute of Drug Abuse grant [grant number RO1 DA 15999-01]; National Health and Medical Research Council Practitioner Research Fellowships to [GD and PH and AL]; a National Health and Medical Research Council Career Development Award and a VicHealth Senior Research Fellowship to [MH] and National Health and Medical Research Council Research Fellowship to [JK].The Kirby Institute for Infection and Immunity in Society is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, University of New South Wales. Roche Pharmaceuticals supplied financial support for pegylated IFN-alpha-2a/ribavirin.